Neuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox Foundation
$2.5 million grant supports clinical trial activation and patient screening efforts for precision medicine approach targeting LRRK2-driven Parkinson’s disease at four clinical sites in Israel
Neuron23® Inc., a clinical-stage biotechnology company on a mission to transform the future of Parkinson’s disease through precision medicine, today announced it has received a $2.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support expansion of the Company’s ongoing Phase 2 NEULARK clinical trial of NEU-411 into Israel.
The funding supports activation of four clinical trial sites across Israel and patient screening efforts for people with early Parkinson’s disease (PD) who may have LRRK2-driven disease. Neuron23 recently screened the first patient in Israel for participation in the NEULARK study.
“Support from The Michael J. Fox Foundation underscores the growing momentum behind precision medicine approaches in Parkinson’s disease,” said Arash Rassoulpour, Ph.D., Chief Operating Officer of Neuron23. “We believe identifying and treating patients based on the underlying biology driving their disease has the potential to fundamentally change how Parkinson’s disease is treated. Israel has an exceptional Parkinson’s research and clinical community, and we are excited to expand NEULARK to patients there.”
